VANCOUVER, Nov. 16, 2017 /CNW/ – InMed Pharmaceuticals, Inc. (“InMed” or the “Company”) (CSE:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today it will present at the Biopharma Forum on ‘Cannabis-Based Science & Medicine’ conference on Thursday, November 30th and Friday, December 1st, 2017 in Denver, CO.
Dr. Sazzad Hossain, InMed’s Chief Scientific Officer, will be presenting a lecture entitled “Epidermolysis to Glaucoma – Identifying Pathology Candidates for Cannabis-Based Treatments.” This presentation will highlight InMed’s internal process of identifying disease targets for treatment with therapeutic cannabinoid compounds, developing tissue-specific delivery formulations, and innovative approaches to addressing regulatory challenges with cannabinoid-based therapies.
More information on this conference, organized by CBI – a division of UBM, is available at: http://www.cbinet.com/conference/pc17091
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE InMed Pharmaceuticals Inc.